Kimmelman C P, Lucente F E
Department of Otolaryngology-Head and Neck Surgery, New York Eye and Ear Infirmary, New York Medical College, NY 10003.
Ann Otol Rhinol Laryngol. 1989 Sep;98(9):721-5. doi: 10.1177/000348948909800912.
During the past 2 years we have used ceftazidime (Fortaz), a third-generation cephalosporin, in the treatment of eight patients with progressive necrotizing "malignant" external otitis. Ceftazidime is very active against Pseudomonas species and provides penetration into the CSF. Our results suggest that this medication has several advantages over the previously recommended combinations of aminoglycosides and semisynthetic penicillins, including improved cure rate, lower toxicity, and simpler administration schedules. We review our experience with ceftazidime in the treatment of eight patients.